Table 2.

Results of Cox regression and tests of proportional hazards assumption; not displayed are comparisons with unknown

Comparison	Results of regression HR (97.5% CI)	Therneau–Grambsch tests ρ (χ², P)
TR vs. Pre-TMZ era	0.89 (0.85–0.94)	−0.017 (5.7, 0.0169)
TMZ vs. Pre-TMZ era	0.82 (0.78–0.86)	−0.032 (19.2, <0.0001)
BZM-TMZ vs. Pre-TMZ era	0.72 (0.69–0.76)	−0.021 (8.21, 0.0042)
55–69 years vs. 70+ years	0.57 (0.55–0.06)	0.032 (19.0, <0.0001)
40–54 years vs. 70+ years	0.39 (0.37–0.42)	0.081 (120, <0.0001)
18–39 years vs. 70+ years	0.22 (0.20–0.24)	0.055 (57.8, <0.0001)
No prior cancer vs. prior	0.96 (0.91–1.01)	−0.009 (1.68, 0.195)
<5 vs. 5+ cm tumor	0.89 (0.85–0.92)	0.036 (24.9, <0.0001)
Divorced vs. widowed	0.92 (0.84–1.01)	−0.004 (0.25, 0.615)
Single vs. widowed	0.87 (0.80–0.95)	−0.001 (0.03, 0.853)
Married vs. widowed	0.80 (0.75–0.85)	0.010 (1.90, 0.168)
Women vs. men	0.94 (0.91–0.98)	−0.020 (7.69, 0.0055)
Black vs. white	1.02 (0.94–1.11)	−0.007 (0.85, 0.356)
Other vs. white	0.86 (0.78–0.94)	0.002 (0.12, 0.735)
Extensive surgery vs. not	0.68 (0.66–0.71)	0.105 (207, <0.0001)
Radiotherapy vs. not	0.49 (0.46–0.52)	0.233 (969, <0.0001)

CI, confidence interval; HR, hazard ratios; TR, transitional; TMZ, temozolomide; BZM, bevacizumab.